KR102496390B1 - 신경발달 질환 및 장애의 치료 방법 - Google Patents

신경발달 질환 및 장애의 치료 방법 Download PDF

Info

Publication number
KR102496390B1
KR102496390B1 KR1020177000415A KR20177000415A KR102496390B1 KR 102496390 B1 KR102496390 B1 KR 102496390B1 KR 1020177000415 A KR1020177000415 A KR 1020177000415A KR 20177000415 A KR20177000415 A KR 20177000415A KR 102496390 B1 KR102496390 B1 KR 102496390B1
Authority
KR
South Korea
Prior art keywords
day
hda
delete delete
disorder
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177000415A
Other languages
English (en)
Korean (ko)
Other versions
KR20170026457A (ko
Inventor
스티브 청
와 친 분
Original Assignee
디킨 유니버시티
더 플로레이 인스티튜트 오브 뉴로사이언스 앤드 멘탈 헬스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014902173A external-priority patent/AU2014902173A0/en
Application filed by 디킨 유니버시티, 더 플로레이 인스티튜트 오브 뉴로사이언스 앤드 멘탈 헬스 filed Critical 디킨 유니버시티
Publication of KR20170026457A publication Critical patent/KR20170026457A/ko
Application granted granted Critical
Publication of KR102496390B1 publication Critical patent/KR102496390B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Insects & Arthropods (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020177000415A 2014-06-06 2015-06-05 신경발달 질환 및 장애의 치료 방법 Active KR102496390B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014902173 2014-06-06
AU2014902173A AU2014902173A0 (en) 2014-06-06 Methods of treating neurodevelopmental diseases and disorders
PCT/AU2015/050310 WO2015184509A1 (en) 2014-06-06 2015-06-05 Methods of treating neurodevelopmental diseases and disorders

Publications (2)

Publication Number Publication Date
KR20170026457A KR20170026457A (ko) 2017-03-08
KR102496390B1 true KR102496390B1 (ko) 2023-02-03

Family

ID=54765877

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177000415A Active KR102496390B1 (ko) 2014-06-06 2015-06-05 신경발달 질환 및 장애의 치료 방법

Country Status (12)

Country Link
US (3) US9925163B2 (enExample)
EP (1) EP3151824B1 (enExample)
JP (2) JP6598262B2 (enExample)
KR (1) KR102496390B1 (enExample)
CN (1) CN106659704B (enExample)
AU (3) AU2015271652B2 (enExample)
BR (1) BR112016028653A2 (enExample)
CA (1) CA2951288C (enExample)
ES (1) ES3014042T3 (enExample)
MX (1) MX377588B (enExample)
NZ (1) NZ727412A (enExample)
WO (1) WO2015184509A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ727412A (en) 2014-06-06 2023-07-28 Wah Chin Boon Methods of treating neurodevelopmental diseases and disorders
US11197840B2 (en) * 2015-12-04 2021-12-14 Wah Chin BOON Methods of treating or alleviating mental disorders and associated symptoms
CN116570582A (zh) * 2023-05-19 2023-08-11 中国药科大学 10-羟基癸烯酸在制备重度抑郁治疗药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1025185A (en) 1911-03-23 1912-05-07 William J Gruss Regrinder.
JPH0967252A (ja) 1995-09-05 1997-03-11 Zenkoku Royal Jelly Kosei Torihiki Kiyougikai ローヤルゼリーに含まれるトランス−１０−ヒドロキシ−デセン酸を有効成分とするアンジオテンシン転換酵素阻害剤及びインスリン様作用剤
WO2007130581A2 (en) * 2006-05-04 2007-11-15 Hardwicke Susan B Compositions and methods for psychiatric conditions and cognition enhancement
WO2009038110A1 (ja) 2007-09-19 2009-03-26 Nagoya Industrial Science Research Institute 神経栄養因子様作用剤
WO2009154197A1 (ja) * 2008-06-17 2009-12-23 ジャパンローヤルゼリー株式会社 認知障害改善剤
JP6348283B2 (ja) * 2011-01-27 2018-06-27 ニューレン ファーマシューティカルズ リミテッド グリシル−ｌ−２−メチルプロリル−ｌ−グルタミン酸を用いる自閉症スペクトラム障害の治療
US10052319B2 (en) 2012-04-26 2018-08-21 Sumitomo Dainippon Pharma Co., Ltd. Medicament for treating mental and behavioural disorders
CA2870822C (en) * 2012-04-27 2016-06-21 Nippon Zoki Pharmaceutical Co., Ltd. Trans-2-decenoic acid derivative and drug containing same
CN103816307B (zh) * 2014-03-12 2016-09-14 张国显 神经生长再造丸及其制备方法
NZ727412A (en) 2014-06-06 2023-07-28 Wah Chin Boon Methods of treating neurodevelopmental diseases and disorders
US11197840B2 (en) 2015-12-04 2021-12-14 Wah Chin BOON Methods of treating or alleviating mental disorders and associated symptoms

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biomedical Research, 28(5), 261-266, 2007.*
Ciene. Tecnol. Aliment, Campinas, 23(Supl): 62-65, 2003.

Also Published As

Publication number Publication date
US20190314315A1 (en) 2019-10-17
MX377588B (es) 2025-03-10
JP6994613B2 (ja) 2022-01-14
AU2025200041A1 (en) 2025-01-23
JP2017517574A (ja) 2017-06-29
US20180214405A1 (en) 2018-08-02
MX2016016118A (es) 2017-07-26
NZ727412A (en) 2023-07-28
CN106659704B (zh) 2020-03-10
US20170087110A1 (en) 2017-03-30
AU2015271652B2 (en) 2021-05-27
ES3014042T3 (en) 2025-04-16
EP3151824B1 (en) 2025-03-05
US10933043B2 (en) 2021-03-02
CA2951288C (en) 2024-01-02
WO2015184509A1 (en) 2015-12-10
EP3151824C0 (en) 2025-03-05
AU2015271652A1 (en) 2017-01-05
KR20170026457A (ko) 2017-03-08
CN106659704A (zh) 2017-05-10
BR112016028653A2 (pt) 2018-07-10
EP3151824A4 (en) 2017-12-20
CA2951288A1 (en) 2015-12-10
JP6598262B2 (ja) 2019-10-30
JP2019214623A (ja) 2019-12-19
AU2021221914A1 (en) 2021-09-23
EP3151824A1 (en) 2017-04-12
US9925163B2 (en) 2018-03-27
US10251856B2 (en) 2019-04-09

Similar Documents

Publication Publication Date Title
AU2025200041A1 (en) Methods of treating neurodevelopmental diseases and disorders
JP2019511495A (ja) ＧＳＫ３β阻害薬チデグルシブによるＣＤＫＬ５障害の治療
US20220117925A1 (en) Methods of treating or alleviating mental disorders and associated symptoms
TW201605443A (zh) 治療ｘ染色體脆折症及相關病症的方法
US20240398855A1 (en) Bromide source for use in treating autism spectral disorder
HK1232805A1 (en) Methods of treating neurodevelopmental diseases and disorders
CN113453761A (zh) 皮特-霍普金斯综合征的治疗
US11583561B2 (en) Composition for preventing, treating, or alleviating viral infection diseases or respiratory diseases comprising vesicle derived from Lactobacillus paracasei
WO2024194737A1 (en) Bacillus amyloliquefaciens strains art12 and art24 for the treatment of disorders of the cns
CN113423406A (zh) 用于治疗皮特-霍普金斯综合征的米诺环素

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4